Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade in Pretreated MALT Lymphoma
NCT00210327Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Jul 2005
- Primary completion
- Nov 2008
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue, sponsored by International Extranodal Lymphoma Study Group. Primary endpoint: Overall Response Rate. Started Jul 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue
Beyond the preview
Go deeper on NCT00210327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00210327.